The US Department of Defense, in coordination with the Department of Health and Human Services, announced they had awarded a $69.3 million contract to CONTINUUS Pharmaceuticals Inc. on January 15, 2021.
The contract is to develop a domestic production capability for critical active pharmaceutical ingredients (APIs) and final dosage form medicines using their proprietary integrated continuous manufacturing (ICM) technology. ICM enables rapid, on-demand production of medicines from API to final dosage form without interruption in a fully-automated, small-footprint facility.
Massachusetts-based CONTINUUS leverages, a novel continuous manufacturing platform, was initially developed through an $85 million joint research project between Novartis and MIT. This new investment will enable CONTINUUS to commercialize its small-footprint, end-to-end pharmaceutical manufacturing technology.
